HIV-1-specific broadly neutralizing antibodies (bNAbs) can protect rhesus monkeys against simian-human immunodeficiency virus (SHIV) challenge. However, the site of antibody interception of virus and the mechanism of antibody-mediated protection remain unclear. We administered a fully protective dose of the bNAb PGT121 to rhesus monkeys and challenged them intravaginally with SHIV-SF162P3. In PGT121-treated animals, we detected low levels of viral RNA and viral DNA in distal tissues for seven days following challenge. Viral RNA-positive tissues showed transcriptomic changes indicative of innate immune activation, and cells from these tissues initiated infection after adoptive transfer into naïve hosts. These data demonstrate that bNAb-mediated protection against a mucosal virus challenge can involve clearance of infectious virus in distal tissues.
M ultiple broadly neutralizing antibodies (bNAbs) targeting HIV-1 envelope (Env)
have demonstrated complete protection against simian-human immunodeficiency virus (SHIV) challenges in rhesus monkeys (1) (2) (3) (4) (5) (6) and are currently being evaluated as a strategy to prevent HIV-1 acquisition in humans. However, the anatomic sites and mechanisms of antibody-mediated protection have not been fully elucidated. In particular, it remains unclear whether bNAbs completely block virus at the local portal of entry after mucosal virus challenge. To address this question, we performed comprehensive necropsies following intravaginal SHIV-SF162P3 challenge of rhesus monkeys that received a fully protective dose of the potent V3 glycan-dependent bNAb, PGT121 (7) .
We verified the protective efficacy of PGT121 against intravaginal challenge with SHIV-SF162P3 (8-10) in a preliminary study in 12 female rhesus monkeys (Macaca mulatta). Consistent with previously published data (1) , an intravenous infusion of 2 mg PGT121 per kilogram of body weight (mg/kg) afforded complete protection against intravaginal challenge with 5 × 10 4 median tissue culture infectious dose (TCID 50 ) SHIV-SF162P3, as evidenced by no detectable plasma viral RNA for more than 6 months following challenge (fig. S1). To evaluate the mechanism of this observed protection, 24 female rhesus monkeys received 2 mg/kg PGT121 (N = 12) or an isotype-matched sham control antibody (N = 12) by the intravenous route on day -1 and were challenged intravaginally with 5 × 10 4 TCID 50 SHIV-SF162P3 on day 0. Serum PGT121 levels were 20 to 50 mg/ml on the day of challenge in all animals. We performed serial necropsies on day 1 (N = 4), day 3 (N = 4), day 7 (N = 10), and day 10 (N = 6) following challenge for comprehensive assessments of virologic, immunologic, and transcriptomic profiles in multiple tissues in each animal (11) .
Tissue viral RNA levels were quantified by an ultrasensitive nested reverse transcription polymerase chain reaction assay (12) , which assessed 30 independent tissues from each animal from the female reproductive tract, draining lymph nodes, gastrointestinal tract, distal lymph nodes, tonsil, spleen, bone marrow, thymus, lung, liver, and central nervous system. In 75% (three out of four) of PGT121-treated animals on day 1 and day 3 following SHIV challenge, we observed low levels of viral RNA in at least one tissue distal to the female reproductive tract, primarily in draining lymph nodes and gastrointestinal tissue (Fig.  1A) . Viral RNA was observed more frequently in PGT121-treated animals than in sham controls at these time points (P = 0.02, two-sided Fisher's exact test) (Fig. 1A) ; this observation suggested that the antibody may have facilitated translocation of virus across the mucosal barrier. On day 7, viral RNA distal to the female reproductive tract was still detected sporadically in 75% (three out of four) of PGT121-treated animals but was not detected in plasma. Viral RNA was detected far more extensively in sham controls than in PGT121-treated animals on day 7 (P = 0.01) (Fig. 1B) . On day 10, viral RNA was not detected in any PGT121-treated animals at distal sites but was present at high levels in all tissues in the sham controls (P = 0.01), as expected (13) (14) (15) (Fig. 1C) .
Viral DNA was also observed sporadically and at a declining frequency in PGT121-treated animals on days 1, 3, and 7 after challenge (Fig. 2 , A to C). In contrast, viral DNA was detected at increasing magnitude and frequency over time in the sham controls, as expected. Taken together, these data show that low but declining levels of viral RNA and viral DNA were detectable in distal tissues in PGT121-treated animals for~7 days following SHIV-SF162P3 challenge but were undetectable by day 10 ( Figs. 1 and 2 and fig. S2 ).
In our SHIV-SF162P3 challenge stock, the level of viral gag RNA (7.5 × 10 8 copies/ml) was~3 logs as great as the corresponding level of viral gag DNA (7.9 × 10 5 copies/ml) (Fig. 2D ). In the four animals that exhibited viral DNA in distal tissues on days 1 to 7 (BD66, CP20, E41, and 6345), the median level of viral RNA (6.9 × 10 3 copies/10 (Fig. 2D) . Moreover, in the day 1 genitalpelvic lymph node from monkey BD66, viral RNA and viral DNA were detected in purified (>99%) CD4 + T lymphocytes (Fig. 2E ). These data suggest that the viral DNA detected in distal tissues reflected a limited degree of new virus replication at the distal sites.
We next assessed Gag-specific CD8 + and CD4 + T lymphocyte responses in multiple tissues from each animal by multiparameter intracellular cytokine staining assays (16, 17) . CD8 + T lymphocyte responses were not detected in any tissue at any time point in the PGT121-treated animals, but these responses were observed in the female genital tract in all sham controls on day 7 and day 10 (figs. S3 to S5). The lack of detectable T lymphocyte responses in the PGT121-treated animals indicates insufficient antigen exposure to induce measurable cellular immune responses and suggests that virus-specific T cell responses were likely not responsible for the clearance of virus in distal tissues at these early time points.
We next evaluated gene expression profiles in multiple tissues in each animal at necropsy (11, 18) . A multidimensional scaling plot revealed differences between PGT121-treated animals and controls for all tissues analyzed ( fig. S6) . We compared transcriptomic profiles in viral RNA-positive compared with viral RNA-negative tissues in the PGT121-treated animals. Inflammasome-related genes [P = 0.00013; the NLR domain, pyrin domain containing 3 (NLRP3), Toll-like receptor genes], and interferon-stimulated genes [P = 0.000046; IFITM2, interleukin 8 (IL8), S100A8] were upregulated specifically in viral RNA-positive local and distal tissues from animals that received PGT121 (Fig. 3A and fig. S7 ). Pathway analysis (19) confirmed up-regulation of several pathways associated with host response to viruses (interferon-a and interferon-b) and cellular activation (hypoxia, tumor necrosis factor signaling via nuclear factor kB, and Janus kinase signal transducers and activators of transcription signaling) in these tissues ( fig. S8 ). Moreover, a linear regression analysis revealed a transcriptomic signature that correlated with viral RNA levels in PGT121-treated animals necropsied on days 1, 3, and 7 (P = 0.00029) (Fig. 3B) . Network inference analysis (20, 21) ) (Fig. 3C and fig. S9 ). We also observed an increase in the number of differentially expressed total and interferonstimulated genes over the first 7 days in viral RNA-positive tissues from PGT121-treated animals ( fig. S10) . By day 7, up-regulation of classic antiviral restriction factors such as IRF7, TRIM5, animals were infectious, we adoptively transferred 30 million cells from the following animals and tissues into naïve hosts by the intravenous route: BD66 (genital-pelvic lymph node; day 1), CP20 (ileocecal lymph node; day 3), and 6345 (spleen; day 7). Tissues from BD66 and 6345 were positive for both viral RNA and viral DNA, whereas tissues from CP20 were negative for viral RNA but positive for viral DNA. Adoptive transfer of cells from BD66 and 6345 into naïve hosts efficiently transferred infection, resulting in 5.8 to 7.1 log RNA copies/ml of replicating virus by day 7 after adoptive transfer (Fig. 4) and demonstrating that the viral RNA and viral DNA detected in these samples included replicationcompetent infectious virus when removed from the host milieu of antibody and innate factors. Cells from CP20 did not detectably transfer infection; this suggests that the amount of virus in this sample was too low or that the viral DNA in this sample was defective and noninfectious.
In summary, we detected low levels of viral RNA and/or viral DNA in at least one tissue distal to the female reproductive tract in 87.5% (seven of eight) of monkeys on days 1, 3, and 7 following intravaginal SHIV-SF162P3 challenge, despite receiving a fully protective dose of PGT121 ( fig. S12 ). Virus in distal tissues triggered transcriptomic responses involving activation of innate immunity and antiviral pathways, and a subset of these samples proved infectious after adoptive transfer into naïve hosts. These data demonstrate that PGT121 did not completely block the challenge virus at the mucosal portal of entry. Instead, some virions appeared to transit to distal tissues, where they were progressively cleared over a period of~7 days and potentially involved Fc effector mechanisms, such as antibodydependent cellular cytotoxicity. The viral RNA to viral DNA ratio at distal sites (Fig. 2D) , the presence of viral RNA and viral DNA in purified CD4 + T lymphocytes (Fig. 2E) , and the transcriptomics signatures ( fig. S11 ) suggested a limited degree of new virus replication at distal sites.
Although our studies were limited to PGT121, it is likely that other bNAbs, as well as vaccineelicited antibodies (9) , also involve viral clearance in distal tissues rather than complete blockade of virus at the mucosal surface. These data emphasize the potential importance of antibodies to clear virally infected cells in tissues to block the establishment of chronic infection (9, (23) (24) (25) . These data are also consistent with previous findings from our laboratory and others that the virus can disseminate rapidly and trigger inflammatory responses in host tissues following mucosal challenge (11, (26) (27) (28) . Moreover, our findings are consistent with the observation that bNAbs may be able to abort initial infection in infant rhesus monkeys when administered therapeutically after SHIV challenge (29) . The possibility that PGT121 may have actually facilitated virus translocation across the mucosal barrier, potentially via immune complexes captured on Fc receptorbearing cells, warrants further investigation.
Our findings have important implications for the development of vaccines, passively transferred antibodies, and other interventions to block HIV-1 infection. In particular, our data suggest that a systemic component of an antiviral intervention may be necessary for optimal efficacy to clear early foci of disseminated virus in distal tissues. It is noteworthy that high concentrations of topically applied bNAbs are required to protect against mucosal SHIV challenge, whereas much lower serum concentrations of intravenously administered bNAbs are required for protection (30, 31) . Our data also show that the initial virus that is seeded in distal tissues may still be vulnerable to immune-mediated elimination before the establishment of a permanent viral reservoir. Further exploitation of this vulnerability may lead to improved HIV-1 eradication strategies, as well as improved HIV-1 prevention strategies. Fig. 4 . Adoptive transfer studies. Adoptive transfer of 30 million cells into naïve hosts by the intravenous route from tissues from BD66 (genital-pelvic lymph node from day 1), CP20 (ileocecal lymph node from day 3), and 6345 (spleen from day 7). Plasma viral RNA copies/ml are shown following adoptive transfer.
